Ulcerative Colitis

Investigators observed clinical response in 15 patients (83%) who underwent the second IV reinduction. Three patients (17%) did not respond and were taken off the therapy.

In data presented during the annual ACG meeting, investigators show vedolizumab can be safe and effective for treating pediatric patients with IBD who have failed anti-TNF therapy.

In a new poster presented at the annual ACG meeting in San Antonio, researchers compare morbidity and mortality for ulcerative colitis patients with or without C. diff or CMV infections.

Ustekinumab (Stelara) has received approval from the US Food and Drug Administration for the treatment of moderate to severely active ulcerative colitis in adults.

Data from a 961-patient study shows that ustekinumab can induce and maintain remission for patients with moderate-to-severe ulcerative colitis.

Investigators discover vedolizumab induces endoscopic remission in 33% of Crohn’s disease patients and histologic remission in 66% of patients after 52 weeks.

Recent measures in the UK has led to a drop in IBD patients using corticosteroids to excess.

In a new trial, investigators test whether continuing or discontinuing ADA is more beneficial.

The largest improvements for patients taking ustekinumab occurred following treatment every 8 weeks.

The AGA-approved guidelines call for a variety of different testing to better diagnose IBS-D in adults.

The FDA-approved drug targets IBS-C patients by increasing bowel movements, while lowering abdominal pain.

In an extensive population-based study, investigators link children with IBD with an increased risk of any psychiatric disorder.

In a new multivariable regression study, investigators link depression with a lack of social support and increased IBD activity.

A further examination of data from a research clinical database shows the risk of smoking outweigh any potential benefits for UC patients.

New evidence from a cumulative RCT analysis suggests irritable bowel syndrome patients do not definitively benefit from FMT treatment.